CA2155109A1 - Utilisation d'une composition pharmaceutique renfermant une quantite efficace d'interleukine-10, un analogue et (ou) un agoniste d'interleukine-10 - Google Patents

Utilisation d'une composition pharmaceutique renfermant une quantite efficace d'interleukine-10, un analogue et (ou) un agoniste d'interleukine-10

Info

Publication number
CA2155109A1
CA2155109A1 CA002155109A CA2155109A CA2155109A1 CA 2155109 A1 CA2155109 A1 CA 2155109A1 CA 002155109 A CA002155109 A CA 002155109A CA 2155109 A CA2155109 A CA 2155109A CA 2155109 A1 CA2155109 A1 CA 2155109A1
Authority
CA
Canada
Prior art keywords
cells
medicament
prevention
diseases
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002155109A
Other languages
English (en)
Inventor
Daniel Abramowicz
Michel Goldman
Thierry Velu
Fabienne Willems
Vincent Donckier
Liliane Schandene
Olivier Pradier
Arnaud Marchant
Catherirne Gerard
Anne Delvaux
Paul Capel
Catherine Bruyns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2155109A1 publication Critical patent/CA2155109A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002155109A 1993-02-01 1994-02-01 Utilisation d'une composition pharmaceutique renfermant une quantite efficace d'interleukine-10, un analogue et (ou) un agoniste d'interleukine-10 Abandoned CA2155109A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93400242.9 1993-02-01
EP93400242 1993-02-01

Publications (1)

Publication Number Publication Date
CA2155109A1 true CA2155109A1 (fr) 1994-08-18

Family

ID=8214672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002155109A Abandoned CA2155109A1 (fr) 1993-02-01 1994-02-01 Utilisation d'une composition pharmaceutique renfermant une quantite efficace d'interleukine-10, un analogue et (ou) un agoniste d'interleukine-10

Country Status (5)

Country Link
EP (1) EP0681589A1 (fr)
JP (1) JPH08510719A (fr)
AU (1) AU6000894A (fr)
CA (1) CA2155109A1 (fr)
WO (1) WO1994017773A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756871A1 (fr) * 1995-08-01 1997-02-05 Institut Pasteur Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
EP0845994A1 (fr) * 1995-08-09 1998-06-10 Schering Corporation Utilisation combinee d'interleukine-10 et de cyclosporine pour une therapie immunosuppressive
AU7847698A (en) * 1996-12-09 1998-07-03 Ariad Gene Therapeutics, Inc. Expression of proteins for treating asthma via ligand mediated activation of their encoding genes
EP1284747A2 (fr) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions et procedes pour obtenir une suppression immune
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
DK1565183T3 (da) 2002-11-29 2008-12-01 Maria Grazia Roncarolo Rapamycin og IL-10 til behandling af autoimmune sygdomme
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
RU2538613C2 (ru) * 2012-10-11 2015-01-10 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук Интерлейкин-10, его применение и композиция на его основе для лечения нейродегенеративных процессов в мозге
EP2986306A4 (fr) 2013-04-18 2016-12-07 Armo Biosciences Inc Méthodes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
CA2914837A1 (fr) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Methode d'evaluation de l'identite et de la stabilite d'une proteine
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2015187295A2 (fr) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Méthodes permettant de faire baisser le cholestérol sérique
EP3206713A4 (fr) 2014-10-14 2018-06-27 Armo Biosciences, Inc. Compositions d'interleukine-15 et leurs utilisations
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
WO2016191587A1 (fr) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Interleukine 10 pégylée utilisée pour le traitement du cancer
CA2995120A1 (fr) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Procedes d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
JP6956950B2 (ja) * 2016-12-27 2021-11-02 国立研究開発法人国立循環器病研究センター リポソーム組成物及び炎症性疾患用治療剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004979A2 (fr) * 1988-11-03 1990-05-17 Schering Corporation Procede de prevention et de reduction de l'eosinophilie
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
NZ249754A (en) * 1992-03-04 1997-06-24 Schering Corp Interleukin-10 and its use in inhibiting graft vs host disease or tissue rejection
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
KR0170037B1 (ko) * 1992-08-20 1999-02-01 에릭 에스. 딕커 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물

Also Published As

Publication number Publication date
JPH08510719A (ja) 1996-11-12
WO1994017773A2 (fr) 1994-08-18
WO1994017773A3 (fr) 1994-12-22
AU6000894A (en) 1994-08-29
EP0681589A1 (fr) 1995-11-15

Similar Documents

Publication Publication Date Title
EP0681589A1 (fr) Utilisation d'une composition pharmaceutique comprenant une dose efficace d'interleukine-10, d'un analogue et/ou d'un agoniste d'interleukine-10
Salomon et al. Tumor necrosis factor α and regulatory T cells in oncoimmunology
Walzer et al. Natural-killer cells and dendritic cells:“l'union fait la force”
Cui et al. Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Vα14 natural killer T cells
Cerboni et al. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK-cell lysis
Thomson et al. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances
JP2883201B2 (ja) Ｃｄ２８刺激関連免疫療法
KR0170037B1 (ko) 인터루킨-4 및/또는 인터루킨-10을 함유하는 약제학적 조성물
Yang et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation
Karimi et al. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT
Chakraborty et al. Complement after trauma: suturing innate and adaptive immunity
Nickerson et al. Prolonged islet allograft acceptance in the absence of interleukin 4 expression
Kim et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7–1 in initiation versus progression of graft arteriosclerosis
SK288048B6 (sk) Use of a substance effective in modulating signal transduction mediated by AILIM for suppressing, treating or preventing graft rejection and pharmaceutical composition comprising the substance for use in suppressing, treating or preventing graft rejection
Benichou et al. Innate immunity and resistance to tolerogenesis in allotransplantation
JP2007056034A (ja) Ｃｄ２８経路免疫調節
Chong et al. Immunobiologics in the treatment of psoriasis
Stirling et al. New immunological approaches and cytokine targets in asthma and allergy
CA2253803A1 (fr) Utilisation d'interleukine-10 pour produire une population de lymphocytes suppresseurs
Laskowski et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats
US20250099542A1 (en) Method of treating a tumor with a combination of il-7 protein and vegf antagonist
Arai et al. Preventing effect of anti-ICAM-1 and anti-LFA-1 monoclonal antibodies on murine islet allograft rejection
Lu et al. Prevention of lethal acute graft-versus-host disease in mice by oral administration of T helper 1 inhibitor, TAK-603
Bullens et al. Effects of co-stimulation by CD58 on human T cell cytokine production: a selective cytokine pattern with induction of high IL-10 production
Green et al. T cell receptor stimulation, but not CD28 costimulation, is dependent on LFA‐1‐mediated events

Legal Events

Date Code Title Description
FZDE Dead